TGFβ in pancreas and colorectal cancer: opportunities to overcome therapeutic resistance.
Allan M JohansenSteven D ForsytheCallum Thomas McGrathGrayson W BarkerHugo JimenezRavi Kumar PaluriBoris C PaschePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
TGFβ is a pleiotropic signaling pathway, which plays a pivotal role in regulating a multitude of cellular functions. TGFβ has a dual role in cell regulation where it induces growth inhibition and cell death; however, it can switch to a growth-promoting state under cancerous conditions. TGFβ is upregulated in CRC and pancreatic cancer, altering the tumor microenvironment, immune system, and promoting a mesenchymal state. The upregulation of TGFβ in certain cancers leads to resistance to immunotherapy, and attempts to inhibit TGFβ expression have led to reduced therapeutic resistance when combined with chemo- and immunotherapy. Here, we review the current TGFβ inhibitor drugs in clinical trials for pancreatic and colorectal cancer, with the goal of uncovering advances in improving clinical efficacy for TGFβ combinational treatments in patients. Furthermore, we discuss the relevance of alterations in TGFβ signaling and germline variants in the context of personalizing treatment for patients who show lack of response to current therapeutics.
Keyphrases